By John Carroll Just a year-and-a-half after buying up promising new diagnostic technology for Parkinson’s, Eli Lilly has signed up for a new collaboration with Medtronic that will marry its biologic approach to treating the disease with a new drug delivery system for the brain. And their partnership earned an endorsement from the Michael J. Fox …
By Maureen Martino Eli Lilly is well aware of the growing challenges of R&D–CEO John Lechleiter has often addressed the topic even as his company faces late-stage setbacks. Now the pharma is taking a new approach to early R&D that will allow it to share the financial burden of drug development. The company plans to raise …
By John Carroll Eli Lilly CEO John Lechleiter took up a favorite topic of his during a speech in London, highlighting the problems that bedevil the R&D field and offering some ideas on how they can be fixed. “Our industry is taking too long, we’re spending too much, and we’re producing far too little,” he …
By Maureen Martino Eli Lilly and Boehringer Ingelheim have teamed on research and commercialization of four drugs–two from Lilly and two from Boehringer–for the treatment of diabetes. And the developers could expand their pact to include work on an anti-TGF-beta monoclonal antibody. The deal covers Boehringer two oral diabetes agents–linagliptin (under regulatory review in the U.S., …
By John Carroll Frustrated by a series of nasty setbacks in the clinic, pharma giant Eli Lilly ($LLY) is writing a $300 million check to acquire Avid Radiopharmaceuticals, a diagnostics company that has garnered worldwide attention for its new approach to detecting Alzheimer’s. Lilly also is promising to pay an additional $500 million provided florbetapir hits certain …
By John Carroll If you’ve got a hot prospect in late-stage development that could start earning cash around, say, 2014, you might want to drop a line to Eli Lilly. Lilly’s research chief, Jan Lundberg, says he’s in the market for some near-term therapeutic prospects–the kind that can help the pharma giant bridge a looming …
By John Carroll Following a series of bitter setbacks in the clinic, Eli Lilly plans to add $150 million to three new biotech venture capital funds that would total $750 million. Lilly venture chief Darren Carroll tellsBloomberg, which broke the story, that the pharma giant expects to cover about 20 percent of each of the …
By John Carroll Eli Lilly’s recent late-stage pratfall in Alzheimer’s set the stage for a blistering Fortune piece dissecting the yawning gap between the Big Pharma’s R&D game plan and its woeful track record. Just as some of its biggest competitors are absorbing pipelines stuffed with potential new products, Lilly has avoided any big merger deals. And …
By Maureen Martino Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs comping off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017. ”We …
By John Carroll Alzheimer’s has long been one of the most difficult and confusing targets in drug development. But lured by the prospect of mega-blockbuster revenue for any new drug that alleviates key symptoms of the memory-wasting disease, Eli Lilly has wagered heavily on two late-stage programs, with more therapies being tested further down the …
